Facioscapulohumeral Muscular Dystrophy (FSHD)


FHSD Society Inks Deal to Expand Clinical Trial Research Network for Disease Impacting 1 Million Worldwide

The facioscapulohumeral muscular dystrophy (FHSD) society inked a memorandum of understanding to enter into three-year expansion of the international FSHD Clinical Trial Research Network (CTRN). Housed at the University of Kansas Medical Center, the FHSD CTRN includes...

Fulcrum Therapeutics Acquires Global Rights to GlaxoSmithKline’s Facioscapulohumeral Muscular Dystrophy Therapy

Fulcrum Therapeutics announced an exclusive worldwide license agreement with GlaxoSmithKline for development and commercialization of the investigational drug losmapimod. Fulcrum intends to advance losmapimod into a Phase 2b trial in the rare and genetic disease...

Pin It on Pinterest